XUNFEIHEALTH

2506
65.2503.76% ( -2.550 )
Delay Closed: Nov 16, 16:08:00

Overview

XUNFEIHEALTH (2506)

Xunfei Healthcare Technology Co., Ltd. provides healthcare AI solutions in the People’s Republic of China. The company offers primary solutions, including a gen...

Open
67.550
High
68.550
Low
65.200
Prev. Close
67.800
Volume
35.65K
Turnover
2.39M
Avg Price
67.052
Bid/Ask Ratio
60.00%
Amplitude
4.94%
52wk High
114.700
Volume Ratio
0.77
Turnover Ratio
0.05%
52wk Low
62.000
HK Mkt Cap
5.04B
Market CapHKD
7.89B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.476
EPSDynamic
-1.13
EPSStatic
--
BVPS
8.16
P/B
8.00
HK Shares
77.30M
Dividend YieldTTM
--
DividendTTM
--
Shares
120.88M
Min lot size
50
Currency
HKD

XUNFEIHEALTH Analyst Rating

View more

Forecast & Rating

Oct 30, 2026
Price forecast
HK$100.5954.17%
Forecast & RatingStrong buy
1analysts
  • Strong buy100.00%
  • Buy0.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Jul, 3

    Xunfei Healthcare staged a rally-fade pattern today, closing 8.3% lower at HKD 74.05 amid heavy afternoon selling pressure, well below the opening price of HKD 80.75. The stock hit an intraday high of HKD 81.40 in the morning session before sliding to an intraday low of HKD 73.00 in the afternoon. Financially, Q4 2025 revenue grew 27.65% YoY to HKD 342.8 million, while net profit surged 429.8% YoY to HKD 5.17 million, though operating income remained negative at -HKD 7.72 million. The current price sits 38.8% below the 52-week high of HKD 121 and trades below both the 20-day MA (HKD 82.35) and 60-day MA (HKD 77.48), suggesting a weak technical position. However, recent news about a strategic MoU to enter the Indonesian market and a Wind ESG A-rating may support long-term prospects.

  2. Jul, 2

    Xunfei Healthcare tumbled during the session, closing at HKD 80.75, down 6.27%. The stock fell steadily from a morning high of HKD 87.50 to HKD 82.85 by midday, then continued to slide to an intraday low of HKD 80.30 in the afternoon before finishing near the day's bottom. The decline was mainly driven by market digestion of the news that its stake in Beijing Huiji had dropped to 49% following a HKD 1.5275 million share subscription, while a strategic AI medical MOU with Indonesia's PT DSST Mas Gemilang signaled overseas growth but failed to offset profit-taking pressure. Q4 revenue rose 27.65% YoY to HKD 3.43 billion, net loss narrowed 429.8% to HKD 5.2 million, and EPS turned positive to HKD 0.0428, marking continued fundamental improvement; however, the stock traded below its 20-day MA of HKD 82.89 and remained 33.26% off the 52-week high of HKD 121.00, with YTD gain of only 5.42% indicating lingering weakness.

News